Assessment of the efficacy and safety of Ribavirin in treatment of coronavirus-related pneumonia (SARS, MERS and COVID-19)

A protocol for systematic review and meta-analysis

Yinhua Wang, MD^a,b, Wen Li, MD^a,c, Zhiming Jiang, MD^d,e,f, Xiuming Xi, MD^a,*, Yibing Zhu, MD^a,g,*

Abstract

Background: The new coronavirus-related pneumonia is causing a global pandemic without specific antiviral drug. Ribavirin has activity against extensive RNA and DNA viruses. We plan to systematically review the use of ribavirin in patients with coronavirus-related pneumonia and meta-analyze the data with updated studies.

Methods: EMBASE, PubMed, Cochrane Library, and China National Knowledge Infrastructure will be searched from 2002 to June 2021 without language restriction to identify randomized controlled trials. Subjects consist of patients with coronavirus-related pneumonia. Ribavirin of any dose or route will be compared with the control group of other medication, placebo, or no medication. The primary outcome is the hospital mortality. The secondary outcome includes the hospital length of stay, ventilator-free days in 28 days, median time from start of study treatment to negative nasopharyngeal swab, and adverse events. The Mantel-Haenszel method will be used for analysis of dichotomous data and the risk ratios will be reported with 95% confidence interval; the inverse-variance method will be used for continuous data and the mean differences will be reported. Sensitivity and subgroup analyses will be further performed. The funnel plots or Egger test will be used for detection of publication bias. The GRADE methodology will be used for summarizing the quality of evidence. The trial sequential analysis will be conducted to test whether the current meta-analysis is conclusive.

Results: The efficacy and safety of ribavirin for treatment of coronavirus-related pneumonia will be systematically reviewed and summarized. The forthcoming results of the ongoing studies focusing on ribavirin in patients with the 2019 novel coronavirus disease will also be included.

Conclusion: The relevant studies will be summarized and advanced evidence will be provided.

PROSPERO registration number: CRD42020178900

Abbreviations: COVID-19 = 2019 novel coronavirus disease, MERS = Middle East respiratory syndrome, MERS-CoV = Middle East respiratory syndrome coronavirus, RCT = randomized controlled trial, SARS = severe acute respiratory syndrome, SARS-CoV = severe acute respiratory syndrome coronavirus, TSA = trial sequential analysis.

Keywords: 2019 novel coronavirus disease, ribavirin, severe acute respiratory syndrome, Middle East respiratory syndrome, systematic review
1. Introduction

The new coronavirus-related pneumonia, COVID-19, is causing a severe public health emergency worldwide.[11] However, no proved vaccines or antivirus treatment has been available so far.[2,3] Ribavirin is a non-interferon-inducing antiviral agent, having activity against extensive RNA and DNA viruses.[4]

During the outbreak of severe acute respiratory syndrome (SARS) in 2003 and Middle East respiratory syndrome (MERS) in 2012, ribavirin was used for antiviral treatment in consideration of its broad-spectrum antiviral activity.[5–7] The studies on ribavirin during SARS and MERS suggested a potential efficacy of using ribavirin; however, the quality of evidence remains low.[7–11] With the previous experience and rationales, ribavirin has also been put into clinical practice in COVID-19. The National Health Commission of China recommended ribavirin intravenous infusion (500mg per time, 2–3 times per day for <10 days, in combination with interferon or lopinavir/ritonavir) in the latest COVID-19 diagnosis and treatment plan (trial version 7).[12]

Through a search on the trial registration website of clinicaltrials.gov and Chinese Clinical Trail Registry (ChiCTR), we found several ongoing randomized controlled trials (RCTs). Therefore, we aim to systematically review the use of ribavirin on coronavirus-related pneumonia (SARS, MERS, and COVID-19) and meta-analyze the data with the results of the updated RCTs to provide advanced evidence.

2. Review question

We aim to assess the safety and efficacy of Ribavirin in treatment of coronavirus-related pneumonia (SARS, MERS and COVID-19).

3. Methods

3.1. Study registration

This meta-analysis has been registered on the PROSPERO (registration number: CRD42020178900) on the PRISMA-P guideline.[13]

3.2. Search methods

Four electronic databases (PubMed, Cochrane Library, EMBASE, and China National Knowledge Infrastructure) will be searched to identify RCTs published from 2002 to June 2021 without language restriction. The potentially relevant references will also be searched. A search strategy using a combination of “coronavirus OR corona virus OR coronavirus-related OR SARS or severe acute respiratory syndrome OR SARS-CoV MERS or middle east respiratory syndrome OR MERS-CoV OR 2019nCoV OR COVID-19 OR SARS-CoV-2 OR novel coronavirus OR NCP” and “ribavirin OR virazole” in all fields has been developed. We also plan to re-run the search before the final analysis.

3.3. Inclusion criteria

3.3.1. Studies. Only RCTs will be included in this analysis.

3.3.2. Participants. The subjects consist of patients diagnosed with SARS, MERS, or COVID-19 of any age.

3.3.3. Interventions/comparators. Ribavirin for the treatment of SARS, MERS, or COVID-19 of any dose or route will be compared with the control group of other medication, placebo, or no medication.

3.3.4. Outcomes. The primary outcome is the hospital mortality. The secondary outcome includes the hospital length of stay, ventilator-free days in 28 days, median time from start of study treatment to negative nasopharyngeal swab, and adverse events.

3.4. Exclusion criteria

The studies only available as the abstract form will be excluded.

3.5. Data collection and analysis

3.5.1. Study screening. Two reviewers (WY and LW) will independently screen the title/abstract of the records after removal of duplicates. The full text will be obtained for further assessment. The potentially relevant studies in the reference lists will also be searched. The flow diagram of selection process will be summarized for report.

3.5.2. Data extraction. Two reviewers (WY and LW) will independently extract the data of first author, year of publication, study design, demographics of subjects, interventions, and outcomes of included studies to fill in a predesigned form. Any discrepancies will be resolved by a consulting group (XX and ZY).

3.5.3. Assessment of study quality. Two reviewers (WY and LW) will independently evaluate the quality of included studies using the Cochrane Collaboration’s tool.[14] The quality of evidence will be assessed using the GRADE methodology.[15,16] Any discrepancies will be solved by XX and ZY.

3.5.4. Statistical analyses and data synthesis. Review Manager 5.3 will be applied for data analyses. For dichotomous data, the Mantel-Haenszel method will be used for the synthesis of risk ratios. For continuous data, the inverse-variance method will be used for the synthesis of mean differences. A 2-sided P value of <.05 will be considered statistically significant.

3.5.5. Assessment of heterogeneity. A χ² test and the statistic I² will be used for assessment of heterogeneities.[17] The F <40% suggests insignificant heterogeneity: 30% to 60% medium; 50% to 90% substantial; 76% to 100% high.[17] Clinical and methodological heterogeneities will be assessed by the 2 reviewers (WY and LW) and discussed with the consulting group (XX and ZY) when needed. If there is no significant statistical, methodological, or clinical heterogeneity, a fixed-effect model will be used. Otherwise, a random-effect model will be chosen.[17]

3.5.6. Subgroup and sensitivity analyses. Subgroup analyses of pneumonia caused by different viruses, different control groups, and different dosage or route of administration will be performed. The sensitivity analysis will be conducted by excluding each single study to test the robustness of the results.

3.5.7. Assessment of publication bias. Funnel plots will be used to assess publication bias when there are >10 studies included. Otherwise, the Egger test will be used.[18,19]

3.5.8. Trial sequential analysis. The trial sequential analysis (TSA) methodology will be used to assess whether the meta-analysis has a sufficient sample size to draw the current conclusion.[20] The Copenhagen TSA software will be used for analyses.
4. Discussion

The in vitro studies showed an antiviral effect on SARS coronavirus (SARS-CoV) and MERS coronavirus (MERS-
CoV).[5,21,22] The pooled clinical data on ribavirin for treatment of SARS or MERS suggested a numerical higher survival rate without statistical significance.[8–10] For safety concerns, there are studies suggesting that ribavirin might be associated with increased incidence of anemia and liver dysfunction.[11,23–26] However, the evidence on SARS and MERS remains mostly based on cohort or case-control studies.[8–11,27] For COVID-19, only in vitro data on the activity of ribavirin on SARS-CoV-2 are available so far.[28] Till now the possible benefit and/or harm of ribavirin for treatment of coronavirus-related pneumonia are still inconclusive. Recently, the epidemic of COVID-19 remains serious in various regions and many clinical trials are designed to provide further evidence. Some ongoing RCTs focusing on ribavirin for COVID-19 can be identified on the registration websites. The forthcoming results of these RCTs will bring us a more comprehensive understanding on ribavirin and its indications. Our systematic review and meta-analysis will include these updated results and re-assess the efficacy and safety of ribavirin in patients with coronavirus-related pneumonia.

Author contributions

Conceptualization: Yibing Zhu, Zhiming Jiang
Data curation: Yinhua Wang, Wen Li
Methodology: Xiuming Xi, Yibing Zhu
Project administration: Yibing Zhu
Software: Wen Li
Supervision: Xiuming Xi
Writing – original draft: Yinhua Wang, Wen Li
Writing – review & editing: Yibing Zhu, Xiuming Xi, Zhiming Jiang

References

[1] Zhu N, Zhang D, Wang W, et al. China Novel Coronavirus Investigating and Research Team A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–33.
[2] Li G, Clercq ED. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2020;19:149–50.
[3] Liu W, Zhou P, Chen K, et al. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. CMAJ 2020;192:E734–44.
[4] Fernandez H, Banks G, Smith R, et al. Ribavirin: a clinical overview. Eur J Epidemiol 1986;2:1–4.
[5] Morgenstern B, Michaels M, Bazer PC, et al. Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun 2003;306:905–8.
[6] Momartin H, Mohammed K, Zamula A, et al. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV): possible lessons from a systematic review of SARS-CoV therapy. Int J Infect Dis 2013;17:e792–8.
[7] Stockman LJ, Bellamy R, Garner P, et al. SARS: Systematic Review of Treatment Effects. PloS Med 2006;3:e343.
[8] Lau EH, Cowling BJ, Muller MP, et al. Effectiveness of ribavirin and corticosteroids for severe acute respiratory syndrome. Am J Med 2009;122:1110.e11–21.
[9] Leong HN, Ang B, Earnest A, et al. Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003. Trop Med Int Health 2004;9:923–7.
[10] Al Ghani M, Alghamdi KM, Ghaithoora Y, et al. Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia. BMC Infect Dis 2016;16:174.
[11] Muller MP, Dresser L, Raboud J, et al. Research Network. Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome. Pharmacotherapy 2007;27:494–503.
[12] National Health Commission of the People’s Republic of China . COVID-19 diagnosis and treatment plan (trial version 7). 2020; Available at: http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4ce80dd7f5912eb1989.shtml. Accessed: 3 March
[13] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
[14] Higgins JPT, Altman DG, Gotzsche PC, et al. Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
[15] Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383–94.
[16] Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401–6.
[17] Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration 2011; Available at: www.cochrane-handbook.org. Accessed: 18 March, 2011
[18] Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–101.
[19] Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997;315:629–34.
[20] Wetzelslev J, Thorlund K, Brok J, et al. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 2008;61:64–75.
[21] Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol 2004;31:69–75.
[22] Hart BJ, Dyall J, Postnikova E, et al. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol 2014;95:571–7.
[23] Knowles SR, Phillips EJ, Dresser L, et al. Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Clin Infect Dis 2003;37:1139–42.
[24] Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003;289:2801–9.
[25] Sung JJ, Wu A, Joly GM, et al. Severe acute respiratory syndrome: Report of treatment and outcome after a major outbreak. Thorax 2004;59:414–20.
[26] Wong WM, Ho JC, Hung IF, et al. Temporal patterns of hepatic dysfunction and disease severity in patients with SARS (4). JAMA 2003;290:2663–5.
[27] Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother 2015;70:2129–32.
[28] Blumraij A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis 2020;72:1987–8.